(firstQuint)Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome.

 PROTOCOL OUTLINE: The patient receives subcutaneous recombinant human insulin-like growth factor 1 daily for 7 months.

 The dose is adjusted according to the serum hormone level and biological markers of bone turnover.

 Concurrent therapy includes a metabolic diet, calcium citrate, and estradiol.

.

 Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome@highlight

OBJECTIVES: I.

 Assess the safety and efficacy of recombinant human insulin-like growth factor 1 in a patient with Werner's syndrome and osteoporosis.

